1. Home
  2. MIRA vs MYNZ Comparison

MIRA vs MYNZ Comparison

Compare MIRA & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRA
  • MYNZ
  • Stock Information
  • Founded
  • MIRA 2020
  • MYNZ 2021
  • Country
  • MIRA United States
  • MYNZ Germany
  • Employees
  • MIRA N/A
  • MYNZ N/A
  • Industry
  • MIRA Biotechnology: Pharmaceutical Preparations
  • MYNZ Biotechnology: Pharmaceutical Preparations
  • Sector
  • MIRA Health Care
  • MYNZ Health Care
  • Exchange
  • MIRA Nasdaq
  • MYNZ Nasdaq
  • Market Cap
  • MIRA 10.9M
  • MYNZ 9.8M
  • IPO Year
  • MIRA 2023
  • MYNZ 2021
  • Fundamental
  • Price
  • MIRA $0.69
  • MYNZ $0.35
  • Analyst Decision
  • MIRA
  • MYNZ Buy
  • Analyst Count
  • MIRA 0
  • MYNZ 2
  • Target Price
  • MIRA N/A
  • MYNZ $3.00
  • AVG Volume (30 Days)
  • MIRA 1.7M
  • MYNZ 1.4M
  • Earning Date
  • MIRA 09-13-2024
  • MYNZ 08-13-2024
  • Dividend Yield
  • MIRA N/A
  • MYNZ N/A
  • EPS Growth
  • MIRA N/A
  • MYNZ N/A
  • EPS
  • MIRA N/A
  • MYNZ N/A
  • Revenue
  • MIRA N/A
  • MYNZ $895,479.00
  • Revenue This Year
  • MIRA N/A
  • MYNZ $67.40
  • Revenue Next Year
  • MIRA N/A
  • MYNZ $191.13
  • P/E Ratio
  • MIRA N/A
  • MYNZ N/A
  • Revenue Growth
  • MIRA N/A
  • MYNZ 69.00
  • 52 Week Low
  • MIRA $0.51
  • MYNZ $0.32
  • 52 Week High
  • MIRA $6.95
  • MYNZ $4.71
  • Technical
  • Relative Strength Index (RSI)
  • MIRA 49.12
  • MYNZ 37.39
  • Support Level
  • MIRA $0.51
  • MYNZ $0.39
  • Resistance Level
  • MIRA $0.89
  • MYNZ $0.46
  • Average True Range (ATR)
  • MIRA 0.10
  • MYNZ 0.07
  • MACD
  • MIRA 0.02
  • MYNZ 0.01
  • Stochastic Oscillator
  • MIRA 38.21
  • MYNZ 13.88

About MIRA MIRA Pharmaceuticals Inc.

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

About MYNZ Mainz Biomed N.V.

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.

Share on Social Networks: